Your browser doesn't support javascript.
loading
Cardiopulmonary Exercise Testing Provides Prognostic Information in Advanced Cystic Fibrosis Lung Disease.
Radtke, Thomas; Urquhart, Don S; Braun, Julia; Barry, Peter J; Waller, Ian; Petch, Nicole; Mei-Zahav, Meir; Kramer, Mordechai R; Hua-Huy, Thong; Dinh-Xuan, Anh Tuan; Innes, J Alastair; McArthur, Sara; Sovtic, Aleksandar; Gojsina, Bojana; Verges, Samuel; de Maat, Tanguy; Morrison, Lisa; Wood, Jamie; Crute, Samantha; Williams, Craig A; Tomlinson, Owen W; Bar-Yoseph, Ronen; Hebestreit, Alexandra; Quon, Bradley S; Kwong, Eugenie; Saynor, Zoe L; Causer, Adam J; Stephenson, Anne L; Schneiderman, Jane E; Shaw, Michelle; Dwyer, Tiffany; Stevens, Daniel; Remus, Natascha; Douvry, Benoit; Foster, Karla; Benden, Christian; Ratjen, Felix; Hebestreit, Helge.
Afiliação
  • Radtke T; Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, and.
  • Urquhart DS; Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, United Kingdom.
  • Braun J; Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, and.
  • Barry PJ; Manchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom.
  • Waller I; Manchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom.
  • Petch N; Manchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom.
  • Mei-Zahav M; Pulmonary Institute, Schneider Children's Medical Center of Israel and Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
  • Kramer MR; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Hua-Huy T; Pulmonary Institute, Schneider Children's Medical Center of Israel and Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
  • Dinh-Xuan AT; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Innes JA; Service de Physiologie-Explorations Fonctionnelles, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France.
  • McArthur S; Service de Physiologie-Explorations Fonctionnelles, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France.
  • Sovtic A; Scottish Adult Cystic Fibrosis Service, Western General Hospital, and.
  • Gojsina B; Respiratory Physiology Service, NHS Lothian, Edinburgh, United Kingdom.
  • Verges S; Mother and Child Health Institute, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • de Maat T; Mother and Child Health Institute, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Morrison L; University Grenoble Alpes, INSERM, CHU Grenoble Alpes, HP2 Laboratory, Grenoble, France.
  • Wood J; University Grenoble Alpes, INSERM, CHU Grenoble Alpes, HP2 Laboratory, Grenoble, France.
  • Crute S; West of Scotland Adult Cystic Fibrosis Unit, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Williams CA; Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Tomlinson OW; Physiotherapy Department, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
  • Bar-Yoseph R; Physiotherapy Department, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
  • Hebestreit A; Children's Health and Exercise Research Centre, Department of Public Health and Sports Science, University of Exeter, Exeter, United Kingdom.
  • Quon BS; Royal Devon University Healthcare NHS Trust, Exeter, Exeter, United Kingdom.
  • Kwong E; Pediatric Pulmonary Institute, Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
  • Saynor ZL; University Children's Hospital Wuerzburg, University Hospital of Wuerzburg, Wuerzburg, Germany.
  • Causer AJ; Adult Cystic Fibrosis Program and.
  • Stephenson AL; Centre for Health Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.
  • Schneiderman JE; Adult Cystic Fibrosis Program and.
  • Shaw M; Centre for Health Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.
  • Dwyer T; School of Sport, Health, and Exercise Science, Faculty of Science and Health, University of Portsmouth, Portsmouth, United Kingdom.
  • Stevens D; Cystic Fibrosis Unit, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Remus N; School of Sport, Health, and Exercise Science, Faculty of Science and Health, University of Portsmouth, Portsmouth, United Kingdom.
  • Douvry B; Cystic Fibrosis Unit, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Foster K; Adult Cystic Fibrosis Center, St. Michael's Hospital.
  • Benden C; Division of Respiratory Medicine, The Hospital for Sick Children.
  • Ratjen F; Kinesiology and Physical Education, and.
  • Hebestreit H; Division of Translational Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
Ann Am Thorac Soc ; 21(3): 411-420, 2024 Mar.
Article em En | MEDLINE | ID: mdl-37879036
Rationale: Cardiopulmonary exercise testing (CPET) provides prognostic information in cystic fibrosis (CF); however, its prognostic value for patients with advanced CF lung disease is unknown. Objectives: To determine the prognostic value of CPET on the risk of death or lung transplant (LTX) within 2 years. Methods: We retrospectively collected data from 20 CF centers in Asia, Australia, Europe, and North America on patients with a forced expiratory volume in 1 second (FEV1) ⩽ 40% predicted who performed a cycle ergometer CPET between January 2008 and December 2017. Time to death/LTX was analyzed using mixed Cox proportional hazards regression. Conditional inference trees were modeled to identify subgroups with increased risk of death/LTX. Results: In total, 174 patients (FEV1, 30.9% ± 5.8% predicted) were included. Forty-four patients (25.5%) died or underwent LTX. Cox regression analysis adjusted for age, sex, and FEV1 revealed percentage predicted peak oxygen uptake ([Formula: see text]o2peak) and peak work rate (Wpeak) as significant predictors of death/LTX: adjusted hazard ratios per each additional 10% predicted were 0.60 (95% confidence interval, 0.43-0.90; P = 0.008) and 0.60 (0.48-0.82; P < 0.001). Tree-structured regression models, including a set of 11 prognostic factors for survival, identified Wpeak to be most strongly associated with 2-year risk of death/LTX. Probability of death/LTX was 45.2% for those with a Wpeak ⩽ 49.2% predicted versus 10.9% for those with a Wpeak > 49.2% predicted (P < 0.001). Conclusions: CPET provides prognostic information in advanced CF lung disease, and Wpeak appears to be a promising marker for LTX referral and candidate selection.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transplante de Pulmão / Fibrose Cística Limite: Humans Idioma: En Revista: Ann Am Thorac Soc Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transplante de Pulmão / Fibrose Cística Limite: Humans Idioma: En Revista: Ann Am Thorac Soc Ano de publicação: 2024 Tipo de documento: Article